Your browser doesn't support javascript.
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.
Yu, Jingyou; Thomas, Paul V; McMahan, Katherine; Jacob-Dolan, Catherine; Liu, Jinyan; He, Xuan; Hope, David; Martinez, Elizabeth J; Chen, Wei-Hung; Sciacca, Michaela; Hachmann, Nicole P; Lifton, Michelle; Miller, Jessica; Powers, Olivia C; Hall, Kevin; Wu, Cindy; Barrett, Julia; Swafford, Isabella; Currier, Jeffrey R; King, Jocelyn; Corbitt, Courtney; Chang, William C; Golub, Emily; Rees, Phyllis A; Peterson, Caroline E; Hajduczki, Agnes; Hussin, Elizabeth; Lange, Camille; Gong, Hua; Matyas, Gary R; Rao, Mangala; Paquin-Proulx, Dominic; Gromowski, Gregory D; Lewis, Mark G; Andersen, Hanne; Davis-Gardner, Meredith; Suthar, Mehul S; Michael, Nelson L; Bolton, Diane L; Joyce, M Gordon; Modjarrad, Kayvon; Barouch, Dan H.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Thomas PV; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • McMahan K; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Jacob-Dolan C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Liu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • He X; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02215, USA.
  • Hope D; Harvard Medical School, Boston, MA 02215, USA.
  • Martinez EJ; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Chen WH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Sciacca M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Hachmann NP; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Lifton M; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Miller J; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Powers OC; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Hall K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Wu C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Barrett J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Swafford I; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Currier JR; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • King J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Corbitt C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Chang WC; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Golub E; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Rees PA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Peterson CE; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Hajduczki A; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Hussin E; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Lange C; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Gong H; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Matyas GR; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Rao M; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Paquin-Proulx D; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Gromowski GD; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Lewis MG; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Andersen H; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Davis-Gardner M; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Suthar MS; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
  • Michael NL; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Bolton DL; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Joyce MG; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Modjarrad K; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
  • Barouch DH; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Sci Adv ; 8(47): eade4433, 2022 Nov 25.
Article in English | MEDLINE | ID: covidwho-2137357
ABSTRACT
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strategies. Here, we assessed the immunogenicity and protective efficacy of two SARS-CoV-2 vaccines targeting the WA1/2020 spike protein, Ad26.COV2.S (Ad26) and Spike ferritin Nanoparticle (SpFN), in nonhuman primates, delivered as either a homologous (SpFN/SpFN and Ad26/Ad26) or heterologous (Ad26/SpFN) prime-boost regimen. The Ad26/SpFN regimen elicited the highest CD4 T cell and memory B cell responses, the SpFN/SpFN regimen generated the highest binding and neutralizing antibody responses, and the Ad26/Ad26 regimen generated the most robust CD8 T cell responses. Despite these differences, protective efficacy against SARS-CoV-2 Omicron BA.1 challenge was similar for all three regimens. After challenge, all vaccinated monkeys showed significantly reduced peak and day 4 viral loads in both bronchoalveolar lavage and nasal swabs as compared with sham animals. The efficacy conferred by these three immunologically distinct vaccine regimens suggests that both humoral and cellular immunity contribute to protection against SARS-CoV-2 Omicron challenge.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Sci Adv Year: 2022 Document Type: Article Affiliation country: Sciadv.ade4433

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Sci Adv Year: 2022 Document Type: Article Affiliation country: Sciadv.ade4433